Modality
Radioligand
MOA
BCMA ADC
Target
KRASG12C
Pathway
Angiogenesis
MyelofibrosisADPKD
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
Jul 2019
→ Aug 2030
Phase 1Current
NCT06595481
853 pts·ADPKD
2021-09→2026-08·Recruiting
NCT05933248
710 pts·ADPKD
2019-07→2030-08·Not yet recruiting
1,563 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-134mo awayPh2 Data· ADPKD
2030-08-074.4y awayPh2 Data· ADPKD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2026-08-13 · 4mo away
ADPKD
Ph2 Data
2030-08-07 · 4.4y away
ADPKD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06595481 | Phase 1/2 | ADPKD | Recruiting | 853 | EFS |
| NCT05933248 | Phase 1/2 | ADPKD | Not yet recr... | 710 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |